Paratek Pharmaceuticals, Inc. announced results of preclinical studies demonstrating that a new class of compounds, orally available non-antibacterial tetracyclines, has shown promising activity in a preclinical animal model of multiple sclerosis (MS). Affecting approximately two million people worldwide, MS is a chronic, inflammatory condition of the nervous system and the most common, non-traumatic, neurological disease in young adults. Dr. David McKenney, a Paratek scientist, will present the findings during an oral presentation at 2:30 p.m. PST (5:30 p.m. EST) today at Neuroscience 2004, the Society for Neuroscience's 34th Annual Meeting in San Diego.
For the first time, Paratek is presenting data showing that its non-antibacterial tetracycline compounds in a preclinical model of MS have efficacy comparable to minocycline, an antibiotic also in the tetracycline family. A previous clinical study directed by Dr. Luanne Metz at the University of Calgary has demonstrated disease protection in MS patients treated with minocycline. Unfortunately, long-term treatment with minocycline or any other broad-spectrum antibiotics causes many patients to experience intolerability related to antibiotic side effects. In today's presentation, Paratek will report that three non-antibacterial tetracycline compounds, with different structures, demonstrated activity in reducing limb paralysis in the preclinical EAE (Experimental Autoimmune Encephalomyelitis) model of MS. These compounds have no detectable antibacterial activity.
Paratek Pharmaceuticals, Inc. and Serono (virt-x: SEO and NYSE: SRA) announced today that they have entered into an agreement to discover, develop and commercialize an orally-available disease modifying treatment for multiple sclerosis (MS). The agreement covers the compounds for which Dr. McKenney presents data today.
Stuart Levy, Paratek's Vice Chairman, Chief Scientific Officer and Co-Founder, commented, "The clinicaPage: 1 2 Related biology news :1
Contact: Katie Compa
. Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels2
. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions3
. SNM presents awards on Capitol Hill4
. ESA presents the sharpest ever satellite map of Earth5
. New book presents neurobiology from an evolutionary perspective6
. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants7
. Childrens Hospital and Research Center-Oakland presents a new maternal diet study8
. USGS presents a world of science at GSA in Philadelphia9
. Childrens Hospital Boston presents at the 2006 American Academy of Pediatrics National Conference10
. DFG presents the 2006 MAK and BAT value list11
. Childrens Hospital Boston presents at the 2006 Pediatric Academic Societies annual meeting